| HOME >> BIOLOGY >> TECHNOLOGY |
BRITISH COLUMBIA, Canada, Sept. 8 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (TSX: IXS.V; OTC Bulletin Board: IXSBF) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces Jeff Morhet, CEO and Chairman, to present during the Wall Street Analyst Forum at the University Club in New York City, Wednesday, September 10, 2008.
CEO and Chairman, Jeff Morhet will provide a company overview, including information about InNexus' unique business strategy, its DXL(TM) technology platform and upcoming company milestones. Investors, venture capitalists, company executives, scientists and other industry leaders will attend the conferences.
The Wall Street Analyst Forum has been a sponsor of annual analyst conferences for NYSE/NASDAQ/AMEX corporations in New York, Boston and London since 1988. The conferences support participating companies by inviting all buy/sell side analyst and portfolio managers to attend while leveraging the use of three new media channels. Over 2,500 public corporations have presented ranging from General Electric, Nokia, Pfizer, Motorola, Inc., Unilever, KB Homes to Adobe Systems.
A live web cast is also available to view online at http://wsw.com/webcast/wsaf7/. Mr. Morhet will be presenting from 9:50-10:30 AM EDT on Wednesday, September 10th.
About InNexus
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management
based in Scottsdal
'/>"/>
| SOURCE InNexus Biotechnology Inc. Copyright©2008 PR Newswire. All rights reserved |